Business
Japan patent for Moditope immunotherapy platform
Japan patent for Moditope immunotherapy platform.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 3658V Scancell Holdings Plc 08 April 2019 \n\n8 April 2019\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell announces grant of Japan patent that protects its Moditope® immunotherapy platform\n \nScancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces that the Japanese Patent Office has granted a patent that provides protection for Scancell's Moditope® immunotherapy platform.\n \nJapanese patent number 6,490,581, entitled Anti-tumour Response to Modified Self-epitopes, covers using any citrullinated tumour-associated T cell epitope to treat patients with cancer. It has a nominal expiry date of August 2033. This grant in Japan follows the grant of patents in the US, Europe, South Africa and Australia, and acceptance for grant in China. Counterparts to these patents continue to be prosecuted in other territories of importance to Scancell in order to further expand Scancell's IP portfolio.\n \nDr Cliff Holloway, Chief Executive Officer, Scancell, said: \n \n\"We are pleased to announce the grant of this patent for Moditope® in Japan, further extending our IP protection around this platform. We look forward to continuing to advance Modi-1, the first product from this platform, towards clinical development.\"\n \nFor Further Information: \n \n\n\n\nScancell Holdings Plc\n\n\n\n\n\n\n\n\n\n\nDr John Chiplin, Chairman\n\n\n\n\n\n+44 (0) 20 3727 1000\n\n\n\n\nDr Cliff Holloway, CEO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPanmure Gordon (UK) Limited \n(Nominated Adviser and Corporate broker)\n\n\n\n\n\n\n\n\n\n\nFreddy Crossley/Emma Earl \n\n\n\n\n\n+44 (0) 20 7886 2500\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting\nSimon Conway/Natalie Garland-Collins\n\n\n\n\n\n+44 (0) 20 3727 1000\n\n\n\n \nAbout Scancell \n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. \n \nImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival. \n \n· SCI...